stockrowDr. Reddy's Laboratories Ltd
RDY Healthcare Drug Manufacturers Specialty & Generic
Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025.
- Revenue
- −10.1%
- EPS
- −36.8%
- Free cash flow
- −70.5%
- Total debt
- +14.1%
Quarter to September 2026, against a year earlier
Follow RDY
Alert me
Dr. Reddy's Laboratories Ltd (RDY) Shares outstanding
Dr. Reddy's Laboratories Ltd's shares outstanding at the end of fiscal 2026 was $833.3M, unchanged from fiscal 2025. At the end of the quarter to 30 September 2026 it was $833.3M. Over the past ten years it has ranged from $830.4M (fiscal 2020) to $855.4M (fiscal 2016); the current reading is higher than 58% of that period. Dr. Reddy's Laboratories Ltd ranks 5th of 81 Drug Manufacturers Specialty & Generic companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2026 | $833.3M | (0.10%) |
| FY2025 | $834.2M | 0.08% |
| FY2024 | $833.5M | 0.19% |
| FY2023 | $831.9M | 0.03% |
| FY2022 | $831.7M | 0.01% |
| FY2021 | $831.6M | 0.14% |
| FY2020 | $830.4M | (0.03%) |
| FY2019 | $830.6M | (0.03%) |
| FY2018 | $830.9M | (0.49%) |
| FY2017 | $835.0M | (2.38%) |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $833.3M | 6.38% |
| Jun 2026 | $783.3M | (6.00%) |
| Mar 2026 | $833.3M | 0.02% |
| Dec 2025 | $833.2M | 0.02% |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| VTRS Viatris Inc. compare | $1.2B |
| RDY Dr. Reddy's Laboratories Ltd | $833.3M |
| ELAN Elanco Animal Health Incorporated compare | $505.9M |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $335.7M |
| HIMS Hims & Hers Health, Inc. compare | $231.7M |
| ALKS Alkermes plc compare | $176.4M |
| NBIX Neurocrine Biosciences, Inc. compare | $105.2M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $84.9M |
| LNTH Lantheus Holdings, Inc. compare | $68.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on RDY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement